Storm Therapeutics Ltd

STORM Therapeutics Limited is a clinical-stage biotechnology company based in Cambridge, England. Founded in 2015 as a spin-out from the University of Cambridge, the company specializes in RNA epigenetics to develop innovative small-molecule therapies aimed at treating cancer, inflammation, viral infections, and CNS diseases. STORM's research focuses on modulating RNA modifying enzymes (RMEs), leveraging expertise from its scientific founders, Professors Tony Kouzarides and Eric Miska. The company is known for its lead product, STC-15, which is the first RME inhibitor in human clinical trials. This product is currently undergoing a Phase 1b/2 study in combination with LOQTORZI™ for various types of cancer. STORM has raised significant funding, totaling approximately $46M–$69.29M, and has been recognized for its innovative drug targets. With a dedicated team of around 33 employees, STORM is committed to advancing drug discovery and clinical development in the healthcare and pharmaceutical sectors.